“Hundreds Sue GLP-1 Drugmakers Over Vision Loss Risks” — what this page in the network covers. Hundreds of Americans are taking legal action against GLP-1 drugmakers Novo Nordisk and Eli Lilly, alleging they were not adequately warned about the potential risk of vision loss associated with their medications. The lawsuits claim that the companies failed to disclose this serious side effect. In response, Novo Nordisk states it is "vigorously" fighting the lawsuits and calls them "without merit." Eli Lilly maintains that "patient safety" is its "top priority." Both companies have issued statements defending their products and practices.
NBC News' Stephanie Gosk reports on the growing legal battle, the patients involved, and what this means for the future of these popular diabetes and weight-loss drugs. The segment provides context on the allegations and the companies' rebuttals, offering a balanced view of a complex controversy. For the complete material, the listing points back to the source inside the network.